HighTower Advisors
SUPN icon

HighTower Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

HighTower Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$766K Buy
14,810
+5,815
+65% +$296K ﹤0.01% 2382
2025
Q4 		$447K Buy
8,995
+2,092
+30% +$102K ﹤0.01% 2711
2025
Q3 		$330K Sell
6,903
-1,053
-13% -$42.4K ﹤0.01% 2965
2025
Q2 		$251K Sell
7,956
-678
-8% -$21.7K ﹤0.01% 3090
2025
Q1 		$283K Sell
8,634
-496
-5% -$17.6K ﹤0.01% 2912
2024
Q4 		$330K Buy
9,130
+624
+7% +$22K ﹤0.01% 2816
2024
Q3 		$264K Buy
+8,506
New +$265K ﹤0.01% 2907
2024
Q1 		– Sell
-13,708
Closed -$395K – 3984
2023
Q4 		$395K Buy
13,708
+1,231
+10% +$32.6K ﹤0.01% 2498
2023
Q3 		$341K Buy
+12,477
New +$380K ﹤0.01% 2495
2023
Q2 		– Sell
-5,962
Closed -$221K – 3679
2023
Q1 		$221K Sell
5,962
-1,270
-18% -$48.8K ﹤0.01% 2681
2022
Q4 		$263K Buy
+7,232
New +$251K ﹤0.01% 2568
2020
Q3 		– Sell
-51,379
Closed -$1.22M – 2690
2020
Q2 		$1.22M Buy
+51,379
New +$1.14M 0.01% 1028
2018
Q4 		– Sell
-4,035
Closed -$203K – 2356
2018
Q3 		$203K Sell
4,035
-190
-4% -$9.38K ﹤0.01% 1951
2018
Q2 		$252K Buy
+4,225
New +$219K ﹤0.01% 1784
2016
Q4 		– Sell
-18,761
Closed -$464K – 2030
2016
Q3 		$464K Buy
+18,761
New +$425K 0.01% 1277
2016
Q2 		– Sell
-20,207
Closed -$306K – 2008
2016
Q1 		$306K Sell
20,207
-1,475
-7% -$19.2K ﹤0.01% 1596
2015
Q4 		$295K Buy
+21,682
New +$335K ﹤0.01% 1581

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's SUPN Position: Q1 2026 in Review

HighTower Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 65% in Q1 2026, buying an estimated $296K and bringing the position to 14,810 shares worth $766K. The position accounts for ﹤0.01% of the portfolio, ranked #2382.

HighTower Advisors first reported a position in SUPN in Q4 2015 and has held it in 17 quarters since. The position peaked at $1.22M in Q2 2020. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • HighTower Advisors held 14,810 shares of Supernus Pharmaceuticals worth $766K as of Q1 2026.
  • HighTower Advisors bought 5,815 Supernus Pharmaceuticals shares in Q1 2026, an estimated $296K.
  • Supernus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2382 holding.
  • HighTower Advisors first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 17 quarters since.
  • HighTower Advisors's Supernus Pharmaceuticals position peaked at $1.22M in Q2 2020.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.